Gastrointestinal adverse events · Patients receiving methotrexate for rheumatoid arthritis
Folinic acid showed no clear difference in GI side effects (nausea, vomiting, abdominal pain) compared with placebo (moderate certainty).
1 finding from 1 review
Stomatitis / mouth sores (incidence) · Patients receiving methotrexate for rheumatoid arthritis
Folinic acid showed no clear difference in stomatitis / mouth sores (incidence) compared with placebo (moderate certainty).
1 finding from 1 review
Liver toxicity (incidence of transaminase elevation) · Patients receiving methotrexate for rheumatoid arthritis
Folinic acid probably leads to lower liver toxicity (incidence of transaminase elevation) compared with placebo (moderate certainty).
1 finding from 1 review
Haematological disorders (neutropenia, etc) · Patients receiving methotrexate for rheumatoid arthritis
Folinic acid showed no clear difference in haematological disorders (neutropenia, etc) compared with placebo (low certainty).
1 finding from 1 review
Acceptability: total withdrawals · Patients receiving methotrexate for rheumatoid arthritis
Folinic acid probably leads to lower total withdrawals compared with placebo (moderate certainty).
1 finding from 1 review
Number of swollen joints with folinic acid (≤7 mg/wk) Change in number of swollen joints · Patients receiving methotrexate for rheumatoid arthritis
1 finding from 1 review
Number of tender joints with folinic acid (≤7 mg/wk) Change in number of tender joints · Patients receiving methotrexate for rheumatoid arthritis
1 finding from 1 review
Gastrointestinal adverse events · Patients receiving methotrexate for rheumatoid arthritis
Folic or folinic acid (any) probably leads to lower GI side effects (nausea, vomiting, abdominal pain) compared with placebo (moderate certainty).
1 finding from 1 review
Stomatitis / mouth sores (incidence) · Patients receiving methotrexate for rheumatoid arthritis
Folic or folinic acid (any) showed no clear difference in stomatitis / mouth sores (incidence) compared with placebo (moderate certainty).
1 finding from 1 review
Liver toxicity (incidence of transaminase elevation) · Patients receiving methotrexate for rheumatoid arthritis
Folic or folinic acid (any) probably leads to lower liver toxicity (incidence of transaminase elevation) compared with placebo (moderate certainty).
1 finding from 1 review
Haematological disorders (neutropenia, etc) · Patients receiving methotrexate for rheumatoid arthritis
Folic or folinic acid (any) showed no clear difference in haematological disorders (neutropenia, etc) compared with placebo (low certainty).
1 finding from 1 review
Acceptability: total withdrawals · Patients receiving methotrexate for rheumatoid arthritis
Folic or folinic acid (any) probably leads to lower total withdrawals compared with placebo (moderate certainty).
1 finding from 1 review
Swollen joints Number of swollen joints Scale from 0 to 28 · Patients receiving methotrexate for rheumatoid arthritis
1 finding from 1 review
Number of tender joints Change in number of tender joints · Patients receiving methotrexate for rheumatoid arthritis
1 finding from 1 review